bioAffinity Technologies Files 8-K on Shareholder Vote Matters
Ticker: BIAFW · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K for a shareholder vote on Oct 2nd. Details on corporate actions to follow.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on October 7, 2024, reporting on a submission of matters to a vote of security holders that occurred on October 2, 2024. The filing details the company's corporate structure and its principal executive offices located in San Antonio, Texas.
Why It Matters
This filing indicates that bioAffinity Technologies, Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can introduce uncertainty regarding corporate governance and strategic decisions.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of earliest event reported
- October 7, 2024 (date) — Date of report
- San Antonio, Texas (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders on October 2, 2024?
The filing states that matters were submitted to a vote of security holders on October 2, 2024, but does not specify the exact nature of these matters within the provided text.
What is the principal business address of bioAffinity Technologies, Inc.?
The principal executive offices of bioAffinity Technologies, Inc. are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
When was this 8-K filing submitted?
This 8-K filing was submitted on October 7, 2024.
What is the state of incorporation for bioAffinity Technologies, Inc.?
bioAffinity Technologies, Inc. is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for bioAffinity Technologies, Inc. is 46-5211056.
Filing Stats: 745 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-10-07 08:00:13
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 51KB
- 0001493152-24-039644.txt ( ) — 271KB
- biaf-20241002.xsd (EX-101.SCH) — 4KB
- biaf-20241002_def.xml (EX-101.DEF) — 29KB
- biaf-20241002_lab.xml (EX-101.LAB) — 36KB
- biaf-20241002_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer